最高的爱人诏,老色哥,美发店的待遇2

D77

NMR下載 COA and HPLC MSDS下載
names：
D77
CAS號：
497836-10-9
MDL Number：
MF(分子式)： C28H22BrNO7S MW(分子量)： 596.45
EINECS: Reaxys Number:
Pubchem ID:6007633 Brand:BIOFOUNT

D77(497836-10-9)是一種抗HIV-1抑制劑，通過作用于整合酶與細胞LEDGF / p75的相互作用，D77抑制HIV-1（IIIB）復制，作用于MT-4細胞時，EC50值23.8μg/ ml（C8166細胞時，EC50值5.03μg/ ml）

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
YZM000696-5mg	5mg	>97%	￥ 3543.00	￥ 3543.00		Backorder	- +	￥ 0.00
YZM000696-2mg	2mg	>97%	￥ 2274.68	￥ 2274.68		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	D77(497836-10-9);D77化合物;D77; D 77; D-77；4-[（5-溴-4-{（Z）-[2,4-二氧代-3-（2-氧代-2-苯基乙基）-1,3-噻唑烷丁-5-亞烷基]甲基] -2-乙氧基苯氧基）甲基]苯甲酸;4-（（5-溴-4-（（2,4-二氧-3-（2-氧代-2-苯基乙基）-1,3-噻唑烷-5-亞甲基）甲基）-2-乙氧基苯氧基）甲基）苯甲酸酸;
英文別名	D77(497836-10-9); D 77; D-77; 4-[(5-Bromo-4-{(Z)-[2,4-dioxo-3-(2-oxo-2-phenylethyl)-1,3-thiazolidin-5-ylidene]methyl}-2-ethoxyphenoxy)methyl]benzoic acid;4-((5-bromo-4-((2,4-dioxo-3-(2-oxo-2-phenylethyl)-1,3-thiazolidin-5-ylidene)methyl)-2-ethoxyphenoxy)methyl)benzoic acid;D77 compound;
CAS號	497836-10-9
Inchi	InChI=1S/C28H22BrNO7S/c1-2-36-23-12-20(21(29)14-24(23)37-16-17-8-10-19(11-9-17)27(33)34)13-25-26(32)30(28(35)38-25)15-22(31)18-6-4-3-5-7-18/h3-14H,2,15-16H2,1H3,(H,33,34)/b25-13-
InchiKey	UZYMVECXXFVCGS-MXAYSNPKSA-N
分子式 Formula	C28H22BrNO7S
分子量 Molecular Weight	596.45
溶解度Solubility
性狀	固體粉末Solid
儲藏條件 Storage conditions	儲存在-20°C

D77(497836-10-9)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags：D77試劑,D77雜質(zhì),D77中間體,D77密度,D77溶解度,D77旋光度,D77結(jié)構(gòu)式,D77購買,D77閃點,D77熔點,

產(chǎn)品說明	D77(497836-10-9)是一種抗HIV-1抑制劑，通過作用于整合酶與細胞LEDGF / p75的相互作用，D77抑制HIV-1（IIIB）復制，作用于MT-4細胞時，EC50值23.8μg/ ml（C8166細胞時，EC50值5.03μg/ ml）
Introduction	D77(497836-10-9)is antiIV inhibitor targeting the interaction between integrase and cellular LEDGF/p75.
Application1	D77 inhibits HIV(IIIB) replication by EC50 value of 23.8 μg/ml in MT cell (5.03 μg/ml for C8166 cells).IC50 value: 23.8 μg/ml (EC50, in MT cell ), 5.03 μg/ml (EC50, in C8166 cell)
Application2	D77是抗HIV-1抑制劑，可抑制HIV-1（IIIB）復制（EC50 = 23.8μM）
Application3

D77(497836-10-9)藥理學：

※D77是一種抗HIV-1抑制劑，通過作用于整合酶與細胞LEDGF / p75的相互作用，D77抑制HIV-1（IIIB）復制，作用于MT-4細胞時，EC50值23.8μg/ ml（C8166細胞時，EC50值5.03μg/ ml）

※D77是抗HIV-1抑制劑，靶向整合酶和細胞LEDGF / p75之間的相互作用。D77在MT-4細胞中的EC50值為23.8μg/ ml，抑制HIV-1（IIIB）復制（對于C8166細胞為5.03μg/ ml）。IC50值：23.8μg/ ml（在MT-4細胞中為EC50），5.03μg/ ml（在C8166細胞中為EC50）目標：體外HIV-1：D77對HIV-1整合酶催化核心具有高度特異性的結(jié)合親和力與未處理D77的細胞相比，D77引起濃度依賴性的α-半乳糖苷酶活性急劇下降。D77揭示了對IN與IBD相互作用的顯著抑制活性.

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem Biophys Res Commun. 2008 Oct 10;375(1):139-144.

Insight into the inhibitory mechanism and binding mode between D77 and HIV-1 integrase by molecular modeling methods.Journal of biomolecular structure & dynamics21875151 2011-10-01

Inhibitors of the interactions between HIV-1 IN and the cofactor LEDGF/p75.ChemMedChem 21506277 2011-07-04

D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75.Biochemical and biophysical research communications.18691

D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75 PMID 18691555; Biochemical and biophysical research commu

D77(497836-10-9)參考文獻：

1、Insight into the inhibitory mechanism and binding mode between D77 and HIV-1 integrase by molecular modeling methods
Ping Li 1, Jian Jun Tan, Ming Liu, Xiao Yi Zhang, Wei Zu Chen, Cun Xin Wang

Abstract Integrase is an essential enzyme in the life cycle of Human immunoficiency virus type 1 (HIV-1) and also an important target for designing integrase inhibitors. In this paper, the binding modes between the wild type integrase core domain (ICD) and the W131A mutant ICD with the benzoic acid derivative--D77 were investigated using the molecular docking combined with molecular dynamics (MD) simulations. The result of MD simulations showed that the W131A substitution affected the flexibility of the region 150-167 in both the monomer A and B of the mutant type ICD. In principle, D77 interacted with the residues around the Lens Epithelium-Derived Growth Factor (LEDGF/p75) binding site which is nearby the HIV-1 integrase dimer interface. However, the specific binding modes for D77-wild type integrase and D77-mutant integrase systems are various. According to the binding mode of D77 with the wild type ICD, D77 can effectively intervene with the binding of LEDGF/p75 to integrase due to a steric hindrance effect around the LEDGF/p75 binding site. In addition, we found that D77 might also affect its inhibitory action by reducing the flexibility of the region 150-167 of integrase. Through energy decomposition calculated with the Molecular Mechanics Generalized Born Surface Area approach to estimate the binding affinity, it seems likely that W131 and E170 are indispensable for the ligand binding, as characterized by the largest binding affinity. All the above results are consistent with the experimental data, providing us with some helpful information not only for the understanding of the mechanism of this kind of inhibitor but also for the rational drug design.

2、Inhibitors of the interactions between HIV-1 IN and the cofactor LEDGF/p75
Laura De Luca 1, Stefania Ferro, Francesca Morreale, Sara De Grazia, Alba Chimirri

Abstract The replication cycle of human immunodeficiency virus type 1 (HIV-1) is a complex multistep process that depends on both viral and host cell factors. The nuclear protein lens epithelium-derived growth factor (LEDGF/p75) is a multidomain protein, present in host cells, which plays an important role in the integration process. LEDGF/p75 not only binds HIV-1 integrase (IN) at its IN binding domain (IBD) but also contains several motifs that function in DNA and chromatin binding. The demonstrated importance of the association between IN and LEDGF/p75 in HIV-1 integration suggests the possibility that this protein-protein interaction (PPI) could be exploited as an antiviral target. We describe herein the progress to date in developing inhibitors of this promising target.

3、D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75
Li Du 1, Yaxue Zhao, Jing Chen, Liumeng Yang, Yongtang Zheng, Yun Tang, Xu Shen, Hualiang Jiang Affiliations expand

Abstract Integration of viral-DNA into host chromosome mediated by the viral protein HIV-1 integrase (IN) is an essential step in the HIV-1 life cycle. In this process, Lens epithelium-derived growth factor (LEDGF/p75) is discovered to function as a cellular co-factor for integration. Since LEDGF/p75 plays an important role in HIV integration, disruption of the LEDGF/p75 interaction with IN has provided a special interest for anti-HIV agent discovery. In this work, we reported that a benzoic acid derivative, 4-[(5-bromo-4-{[2,4-dioxo-3-(2-oxo-2-phenylethyl)-1,3-thiazolidin-5-ylidene]methyl}-2-ethoxyphenoxy)methyl]benzoic acid (D77) could potently inhibit the IN-LEDGF/p75 interaction and affect the HIV-1 IN nuclear distribution thus exhibiting antiretroviral activity. Molecular docking with site-directed mutagenesis analysis and surface plasmon resonance (SPR) binding assays has clarified possible binding mode of D77 against HIV-1 integrase. As the firstly discovered small molecular compound targeting HIV-1 integrase interaction with LEDGF/p75, D77 might supply useful structural information for further anti-HIV agent discovery.

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開